Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting
Know Labs, Inc. (KNW) has been chosen to present an oral abstract at the 2024 American Association of Clinical Endocrinology Annual Meeting. The abstract, titled 'Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning,' will showcase the accuracy and medical application of its proprietary sensor. The company will continue deploying its KnowU™ wearable continuous glucose monitor in large-scale clinical trials toward FDA clearance, focusing on performance in real-world environments and extreme glycemic ranges.
Selection for an oral abstract presentation at the 2024 American Association of Clinical Endocrinology Annual Meeting highlights Know Labs' recognition in the medical community.
The positive results from the clinical study demonstrate the accuracy and medical application of the company's proprietary sensor, showcasing potential for commercial success in non-invasive medical diagnostic technology.
Continued deployment of the KnowU™ wearable continuous glucose monitor in large-scale clinical trials and advancements in model techniques indicate progress towards FDA clearance and potential market acceptance.
- None.
The Company’s oral abstract presentation features results from its clinical study that demonstrate the accuracy and medical application of its proprietary sensor.
The Company will present an abstract titled, “Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning.” Know Labs first announced these interim results in March of this year from its clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting.
During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM) in large-scale, external clinical trials while advancing model techniques and making refinements to the device. These new studies will help determine the technology’s performance throughout continuous wear, in more real-world environments, and within more extreme glycemic ranges (below 70 mg/dL and above 350 mg/dL). To stay updated on the latest results, visit www.knowlabs.co/research-and-development.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509350016/en/
For Know Labs Media Inquiries:
Matter Health
Abby Mayo
Knowlabs@matternow.com
Ph. (617) 272-0592
Know Labs, Inc. Contact:
Jordyn Hujar
jordyn@knowlabs.co
Ph. (206) 629-6414
Source: Know Labs, Inc.
FAQ
What will Know Labs present at the 2024 American Association of Clinical Endocrinology Annual Meeting?
What are the interim results from Know Labs' clinical research protocol?
What is the KnowU™ wearable continuous glucose monitor?
